Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 18; p. 4651
Main Authors Sahin, Katherine B., Shah, Esha T., Ferguson, Genevieve P., Molloy, Christopher, Kalita-de Croft, Priyakshi, Hayes, Sarah A., Hudson, Amanda, Colvin, Emily, Kamitakahara, Hannah, Harvie, Rozelle, Hasovits, Csilla, Khan, Tashbib, Duijf, Pascal H. G., Howell, Viive M., He, Yaowu, Bolderson, Emma, Hooper, John D., Lakhani, Sunil R., Richard, Derek J., O’Byrne, Kenneth J., Adams, Mark N.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 16.09.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy. Herein, we explored whether CDCA3 levels were associated with EGFR mutant LUAD and TKI response. We demonstrate that in a small-cohort tissue microarray and in vitro LUAD cell line panel, CDCA3 protein levels are elevated in EGFR mutant NSCLC as a result of increased protein stability downstream of receptor tyrosine kinase signalling. Here, CDCA3 protein levels correlated with TKI potency, whereby CDCA3high EGFR mutant NSCLC cells were most sensitive. Consistently, ectopic overexpression or inhibition of casein kinase 2 using CX-4945, which pharmacologically prevents CDCA3 degradation, upregulated CDCA3 levels and the response of T790M(+) H1975 cells and two models of acquired resistance to TKIs. Accordingly, it is possible that strategies to upregulate CDCA3 levels, particularly in CDCA3low tumours or upon the emergence of therapy resistance, might improve the response to EGFR TKIs and benefit patients.
AbstractList Simple SummaryResistance to tyrosine kinase inhibitors (TKIs) that target common non-small-cell lung cancer mutations within the epidermal growth factor receptor (EGFR) is a primary clinical issue. The aim of our study was to determine whether the protein cell division cycle-associated protein 3 (CDCA3) might be a biomarker for TKI response in EGFR mutant lung cancer. Our previous work has demonstrated that CDCA3 is a marker of chemotherapy sensitivity in lung cancer. We provide evidence that CDCA3 levels are increased in EGFR mutant lung cancer and these levels are associated with sensitivity to TKIs. In addition, increasing the levels of CDCA3 enhances TKI sensitivity in models of TKI-resistant EGFR mutant lung cancer. Our findings propose that strategies to upregulate CDCA3 levels might improve TKI response in EGFR mutant lung cancer.AbstractTyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy. Herein, we explored whether CDCA3 levels were associated with EGFR mutant LUAD and TKI response. We demonstrate that in a small-cohort tissue microarray and in vitro LUAD cell line panel, CDCA3 protein levels are elevated in EGFR mutant NSCLC as a result of increased protein stability downstream of receptor tyrosine kinase signalling. Here, CDCA3 protein levels correlated with TKI potency, whereby CDCA3high EGFR mutant NSCLC cells were most sensitive. Consistently, ectopic overexpression or inhibition of casein kinase 2 using CX-4945, which pharmacologically prevents CDCA3 degradation, upregulated CDCA3 levels and the response of T790M(+) H1975 cells and two models of acquired resistance to TKIs. Accordingly, it is possible that strategies to upregulate CDCA3 levels, particularly in CDCA3low tumours or upon the emergence of therapy resistance, might improve the response to EGFR TKIs and benefit patients.
Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy. Herein, we explored whether CDCA3 levels were associated with EGFR mutant LUAD and TKI response. We demonstrate that in a small-cohort tissue microarray and in vitro LUAD cell line panel, CDCA3 protein levels are elevated in EGFR mutant NSCLC as a result of increased protein stability downstream of receptor tyrosine kinase signalling. Here, CDCA3 protein levels correlated with TKI potency, whereby CDCA3high EGFR mutant NSCLC cells were most sensitive. Consistently, ectopic overexpression or inhibition of casein kinase 2 using CX-4945, which pharmacologically prevents CDCA3 degradation, upregulated CDCA3 levels and the response of T790M(+) H1975 cells and two models of acquired resistance to TKIs. Accordingly, it is possible that strategies to upregulate CDCA3 levels, particularly in CDCA3low tumours or upon the emergence of therapy resistance, might improve the response to EGFR TKIs and benefit patients.
Author Ferguson, Genevieve P.
Kalita-de Croft, Priyakshi
He, Yaowu
O’Byrne, Kenneth J.
Hasovits, Csilla
Harvie, Rozelle
Adams, Mark N.
Lakhani, Sunil R.
Bolderson, Emma
Molloy, Christopher
Hudson, Amanda
Duijf, Pascal H. G.
Hooper, John D.
Khan, Tashbib
Sahin, Katherine B.
Colvin, Emily
Richard, Derek J.
Shah, Esha T.
Hayes, Sarah A.
Howell, Viive M.
Kamitakahara, Hannah
AuthorAffiliation 9 Cancer Services, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102, Australia
8 University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia
1 Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia; Katherine.sahin@hdr.qut.edu.au (K.B.S.); e.shah@qut.edu.au (E.T.S.); genevieve.ferguson@hdr.qut.edu.au (G.P.F.); christopher.molloy@hdr.qut.edu.au (C.M.); pascal.duijf@qut.edu.au (P.H.G.D.); emma.bolderson@qut.edu.au (E.B.); derek.richard@qut.edu.au (D.J.R.)
2 UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, QLD 4006, Australia; p.kalita@uq.edu.au (P.K.-d.C.); s.lakhani@uq.edu.au (S.R.L.)
7 Department of Medical Genetics, Oslo University Hospital, 0379 Oslo, Norway
4 Mater Research Institute, Translational Research Institute, The University of Queensland, Woolloongab
AuthorAffiliation_xml – name: 7 Department of Medical Genetics, Oslo University Hospital, 0379 Oslo, Norway
– name: 2 UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, QLD 4006, Australia; p.kalita@uq.edu.au (P.K.-d.C.); s.lakhani@uq.edu.au (S.R.L.)
– name: 3 Bill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia; sarah.hayes@sydney.edu.au (S.A.H.); amanda.hudson@sydney.edu.au (A.H.); emily.colvin@sydney.edu.au (E.C.); hannah.kamitakahara@gmail.com (H.K.); Rozelle.harvie@sydney.edu.au (R.H.); Csilla.hasovits@sydney.edu.au (C.H.); viive.howell@sydney.edu.au (V.M.H.)
– name: 9 Cancer Services, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102, Australia
– name: 6 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0136 Oslo, Norway
– name: 4 Mater Research Institute, Translational Research Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia; tashbib.khan@uq.net.au (T.K.); yaowu.he@mater.uq.edu.au (Y.H.); john.hooper@mater.uq.edu.au (J.D.H.)
– name: 1 Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia; Katherine.sahin@hdr.qut.edu.au (K.B.S.); e.shah@qut.edu.au (E.T.S.); genevieve.ferguson@hdr.qut.edu.au (G.P.F.); christopher.molloy@hdr.qut.edu.au (C.M.); pascal.duijf@qut.edu.au (P.H.G.D.); emma.bolderson@qut.edu.au (E.B.); derek.richard@qut.edu.au (D.J.R.)
– name: 5 Centre for Data Science, Queensland University of Technology, Brisbane, QLD 4059, Australia
– name: 8 University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia
Author_xml – sequence: 1
  givenname: Katherine B.
  surname: Sahin
  fullname: Sahin, Katherine B.
– sequence: 2
  givenname: Esha T.
  orcidid: 0000-0002-7626-1085
  surname: Shah
  fullname: Shah, Esha T.
– sequence: 3
  givenname: Genevieve P.
  surname: Ferguson
  fullname: Ferguson, Genevieve P.
– sequence: 4
  givenname: Christopher
  surname: Molloy
  fullname: Molloy, Christopher
– sequence: 5
  givenname: Priyakshi
  orcidid: 0000-0001-8877-7655
  surname: Kalita-de Croft
  fullname: Kalita-de Croft, Priyakshi
– sequence: 6
  givenname: Sarah A.
  surname: Hayes
  fullname: Hayes, Sarah A.
– sequence: 7
  givenname: Amanda
  surname: Hudson
  fullname: Hudson, Amanda
– sequence: 8
  givenname: Emily
  surname: Colvin
  fullname: Colvin, Emily
– sequence: 9
  givenname: Hannah
  orcidid: 0000-0003-2011-0584
  surname: Kamitakahara
  fullname: Kamitakahara, Hannah
– sequence: 10
  givenname: Rozelle
  surname: Harvie
  fullname: Harvie, Rozelle
– sequence: 11
  givenname: Csilla
  surname: Hasovits
  fullname: Hasovits, Csilla
– sequence: 12
  givenname: Tashbib
  orcidid: 0000-0001-5203-0672
  surname: Khan
  fullname: Khan, Tashbib
– sequence: 13
  givenname: Pascal H. G.
  orcidid: 0000-0001-8646-9843
  surname: Duijf
  fullname: Duijf, Pascal H. G.
– sequence: 14
  givenname: Viive M.
  orcidid: 0000-0002-2356-3231
  surname: Howell
  fullname: Howell, Viive M.
– sequence: 15
  givenname: Yaowu
  orcidid: 0000-0002-7828-263X
  surname: He
  fullname: He, Yaowu
– sequence: 16
  givenname: Emma
  surname: Bolderson
  fullname: Bolderson, Emma
– sequence: 17
  givenname: John D.
  orcidid: 0000-0003-1054-8486
  surname: Hooper
  fullname: Hooper, John D.
– sequence: 18
  givenname: Sunil R.
  orcidid: 0000-0003-4067-2760
  surname: Lakhani
  fullname: Lakhani, Sunil R.
– sequence: 19
  givenname: Derek J.
  surname: Richard
  fullname: Richard, Derek J.
– sequence: 20
  givenname: Kenneth J.
  surname: O’Byrne
  fullname: O’Byrne, Kenneth J.
– sequence: 21
  givenname: Mark N.
  orcidid: 0000-0003-1906-5018
  surname: Adams
  fullname: Adams, Mark N.
BookMark eNpdkctvEzEQxi1UREvpmSOWuHDZ1q_144JULWkbNYDUhrPl3cw2rjZ2sXcj5cD_jtMWBJ3LjDQ_fd883qKDEAMg9J6SU84NOetc6CBlyqkWsqav0BEjilVSGnHwT32ITnK-JyU4p0qqN-iQi1oxrcwR-jUbYOtGH-5w86U553gBWxgynoX1Xj3j5S7F7APgax9cBjwPa9_6MSZ8CyH70W_9uMM-4OX1vLqB7PPowohnlxc3-Ov0WH-LobrduGGoGhgGvJj2Zo-zv0OvezdkOHnOx-jHxWzZXFWL75fz5nxRdYKxsZJC9NA6TaFlyhguWsNWUouWdVQryRgDagT0hBFNKe9WXEjV05ZIqYGsan6MPj_pPkztBlYdhDG5wT4kv3FpZ6Pz9v9O8Gt7F7e2HFYqzYvAhyeBLpUFfbAhJmcp0TWzhhPDCvHp2SLFnxPk0W587sq-LkCcsmW1UqImrJYF_fgCvY9TCuUAe0pyzU1NCnX2xzLmnKD_Oy4ldv9_--L__DfBTKKB
CitedBy_id crossref_primary_10_1155_2022_6343760
crossref_primary_10_1002_pro_4572
crossref_primary_10_1016_j_critrevonc_2023_104246
crossref_primary_10_1097_MD_0000000000038581
crossref_primary_10_1016_j_bbcan_2024_189147
crossref_primary_10_1016_j_mrfmmm_2022_111798
Cites_doi 10.5858/arpa.2016-0579-CP
10.3390/ph10010027
10.1158/0008-5472.CAN-06-3339
10.1001/jamaoncol.2015.1066
10.1056/NEJMoa1913662
10.1158/1078-0432.CCR-06-0714
10.1038/s42003-021-02136-8
10.1016/j.jtho.2017.07.011
10.1016/j.lungcan.2020.11.008
10.1038/srep44021
10.1158/0008-5472.226.65.1
10.1158/1078-0432.CCR-12-2246
10.1158/2159-8290.CD-12-0095
10.1056/NEJMoa0904554
10.1016/j.ccr.2006.12.017
10.1038/ncomms11815
10.1016/j.canlet.2012.02.032
10.1016/j.ccell.2020.03.012
10.1002/ijc.29210
10.1371/journal.pmed.0020073
10.1093/nar/gkaa1024
10.6004/jnccn.2010.0056
10.1016/j.jtho.2017.04.018
10.3389/fonc.2021.615967
10.1016/j.canlet.2012.11.051
10.3390/ph13100273
10.1016/S1470-2045(11)70393-X
10.1038/s41591-018-0264-7
10.3322/caac.21492
10.1016/S0960-894X(01)00344-4
10.1056/NEJMoa1713137
10.1056/NEJMoa1612674
10.1016/S0092-8674(03)00232-0
10.1186/s12935-020-01547-7
10.1016/j.febslet.2005.01.055
10.1056/NEJMoa040938
10.1158/1078-0432.CCR-06-1570
10.1172/jci.insight.125693
10.1016/j.cllc.2021.06.006
10.1038/s41419-020-2713-8
10.1186/1471-2407-12-321
10.1158/2159-8290.CD-14-0337
10.3892/or.2015.3792
10.1016/j.jtho.2016.05.019
10.1038/s41467-020-19116-x
10.1158/0008-5472.CAN-08-4055
10.1200/JCO.2017.73.9250
10.18632/oncotarget.13150
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
info:eu-repo/semantics/openAccess
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: info:eu-repo/semantics/openAccess
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
3HK
5PM
DOI 10.3390/cancers13184651
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Biological Science Collection
ProQuest research library
Biological Science Database
Research Library (Corporate)
Publicly Available Content (ProQuest)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
NORA - Norwegian Open Research Archives
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef

Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID 10852_93092
10_3390_cancers13184651
GeographicLocations Australia
GeographicLocations_xml – name: Australia
GroupedDBID ---
3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PIMPY
PQQKQ
PROAC
RPM
TUS
7T5
7TO
7XB
8FK
H94
MBDVC
PQEST
PQUKI
PRINS
Q9U
RIG
7X8
3HK
AAPBV
ABPTK
ADRAZ
C1A
DKF
IPNFZ
N95
5PM
AFPKN
ID FETCH-LOGICAL-c422t-644feba81eb279934b92d684b2c1876222e194ef0208113cd3467f1b0668e0d53
IEDL.DBID RPM
ISSN 2072-6694
IngestDate Tue Sep 17 21:06:25 EDT 2024
Sat Apr 29 05:44:05 EDT 2023
Wed Dec 04 10:45:42 EST 2024
Thu Oct 10 17:38:08 EDT 2024
Fri Dec 06 09:04:40 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-644feba81eb279934b92d684b2c1876222e194ef0208113cd3467f1b0668e0d53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8646-9843
0000-0001-8877-7655
0000-0001-5203-0672
0000-0002-7828-263X
0000-0003-4067-2760
0000-0002-2356-3231
0000-0003-2011-0584
0000-0003-1906-5018
0000-0003-1054-8486
0000-0002-7626-1085
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466783/
PMID 34572879
PQID 2576383950
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8466783
cristin_nora_10852_93092
proquest_miscellaneous_2577450256
proquest_journals_2576383950
crossref_primary_10_3390_cancers13184651
PublicationCentury 2000
PublicationDate 20210916
PublicationDateYYYYMMDD 2021-09-16
PublicationDate_xml – month: 9
  year: 2021
  text: 20210916
  day: 16
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Sos (ref_35) 2009; 69
Mok (ref_36) 2016; 376
Barker (ref_9) 2001; 11
Liu (ref_51) 2020; 11
ref_12
Ramalingam (ref_19) 2020; 382
Thress (ref_41) 2017; 12
Mu (ref_38) 2020; 11
Balak (ref_17) 2006; 12
Chen (ref_28) 2013; 330
Bersanelli (ref_21) 2016; 11
SO (ref_47) 2015; 35
Rosell (ref_7) 2009; 361
Tang (ref_37) 2016; 7
Ettinger (ref_4) 2010; 8
Yun (ref_8) 2007; 11
Okabe (ref_34) 2007; 67
Kildey (ref_25) 2021; 4
Dou (ref_50) 2020; 20
ref_23
Cerami (ref_32) 2012; 2
Soria (ref_20) 2018; 378
Bray (ref_1) 2018; 68
Kosaka (ref_18) 2006; 12
Rosell (ref_6) 2012; 13
Graham (ref_16) 2018; 142
Ayad (ref_27) 2003; 113
Ferlay (ref_2) 2015; 136
Yu (ref_13) 2013; 19
ref_30
Chabon (ref_22) 2016; 7
Martens (ref_31) 2020; 49
Moyer (ref_10) 1997; 57
Yu (ref_15) 2015; 1
Adams (ref_24) 2017; 12
Kilgour (ref_39) 2020; 37
Wang (ref_45) 2017; 7
Hu (ref_29) 2015; 33
Yoshida (ref_26) 2005; 579
Shah (ref_44) 2019; 25
Amann (ref_33) 2005; 65
Izadmehr (ref_49) 2019; 4
ref_42
Bliesath (ref_46) 2012; 322
ref_40
ref_3
Lynch (ref_5) 2004; 350
Cross (ref_11) 2014; 4
ref_48
Mok (ref_14) 2017; 35
Blons (ref_43) 2021; 151
References_xml – volume: 142
  start-page: 163
  year: 2018
  ident: ref_16
  article-title: Worldwide Frequency of Commonly Detected EGFR Mutations
  publication-title: Arch. Pathol. Lab. Med.
  doi: 10.5858/arpa.2016-0579-CP
  contributor:
    fullname: Graham
– ident: ref_48
  doi: 10.3390/ph10010027
– volume: 67
  start-page: 2046
  year: 2007
  ident: ref_34
  article-title: Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-3339
  contributor:
    fullname: Okabe
– volume: 1
  start-page: 982
  year: 2015
  ident: ref_15
  article-title: Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2015.1066
  contributor:
    fullname: Yu
– volume: 382
  start-page: 41
  year: 2020
  ident: ref_19
  article-title: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1913662
  contributor:
    fullname: Ramalingam
– volume: 12
  start-page: 5764
  year: 2006
  ident: ref_18
  article-title: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-0714
  contributor:
    fullname: Kosaka
– volume: 4
  start-page: 638
  year: 2021
  ident: ref_25
  article-title: Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-02136-8
  contributor:
    fullname: Kildey
– volume: 12
  start-page: 1588
  year: 2017
  ident: ref_41
  article-title: Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2017.07.011
  contributor:
    fullname: Thress
– volume: 35
  start-page: 1537
  year: 2015
  ident: ref_47
  article-title: AKT/mTOR Down-regulation by CX-4945, a CK2 Inhibitor, Promotes Apoptosis in Chemorefractory Non-small Cell Lung Cancer Cells
  publication-title: Anticancer Res.
  contributor:
    fullname: SO
– volume: 151
  start-page: 69
  year: 2021
  ident: ref_43
  article-title: PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.11.008
  contributor:
    fullname: Blons
– volume: 7
  start-page: 44021
  year: 2017
  ident: ref_45
  article-title: Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer
  publication-title: Sci. Rep.
  doi: 10.1038/srep44021
  contributor:
    fullname: Wang
– volume: 65
  start-page: 226
  year: 2005
  ident: ref_33
  article-title: Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.226.65.1
  contributor:
    fullname: Amann
– volume: 19
  start-page: 2240
  year: 2013
  ident: ref_13
  article-title: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2246
  contributor:
    fullname: Yu
– volume: 2
  start-page: 401
  year: 2012
  ident: ref_32
  article-title: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0095
  contributor:
    fullname: Cerami
– volume: 361
  start-page: 958
  year: 2009
  ident: ref_7
  article-title: Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0904554
  contributor:
    fullname: Rosell
– volume: 11
  start-page: 217
  year: 2007
  ident: ref_8
  article-title: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2006.12.017
  contributor:
    fullname: Yun
– volume: 7
  start-page: 11815
  year: 2016
  ident: ref_22
  article-title: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms11815
  contributor:
    fullname: Chabon
– volume: 322
  start-page: 113
  year: 2012
  ident: ref_46
  article-title: Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2012.02.032
  contributor:
    fullname: Bliesath
– volume: 37
  start-page: 485
  year: 2020
  ident: ref_39
  article-title: Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.03.012
  contributor:
    fullname: Kilgour
– volume: 57
  start-page: 4838
  year: 1997
  ident: ref_10
  article-title: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
  publication-title: Cancer Res.
  contributor:
    fullname: Moyer
– volume: 136
  start-page: E359
  year: 2015
  ident: ref_2
  article-title: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.29210
  contributor:
    fullname: Ferlay
– ident: ref_12
  doi: 10.1371/journal.pmed.0020073
– volume: 49
  start-page: D613
  year: 2020
  ident: ref_31
  article-title: WikiPathways: Connecting communities
  publication-title: Nucleic. Acids Res.
  doi: 10.1093/nar/gkaa1024
  contributor:
    fullname: Martens
– volume: 8
  start-page: 740
  year: 2010
  ident: ref_4
  article-title: Non-small cell lung cancer
  publication-title: J. Natl. Compr. Canc. Netw.
  doi: 10.6004/jnccn.2010.0056
  contributor:
    fullname: Ettinger
– ident: ref_3
– volume: 12
  start-page: 1071
  year: 2017
  ident: ref_24
  article-title: Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2017.04.018
  contributor:
    fullname: Adams
– ident: ref_23
  doi: 10.3389/fonc.2021.615967
– volume: 330
  start-page: 217
  year: 2013
  ident: ref_28
  article-title: HoxB3 promotes prostate cancer cell progression by transactivating CDCA3
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2012.11.051
  contributor:
    fullname: Chen
– ident: ref_40
  doi: 10.3390/ph13100273
– volume: 13
  start-page: 239
  year: 2012
  ident: ref_6
  article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70393-X
  contributor:
    fullname: Rosell
– volume: 25
  start-page: 111
  year: 2019
  ident: ref_44
  article-title: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0264-7
  contributor:
    fullname: Shah
– volume: 68
  start-page: 394
  year: 2018
  ident: ref_1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA A Cancer J. Clin.
  doi: 10.3322/caac.21492
  contributor:
    fullname: Bray
– volume: 11
  start-page: 1911
  year: 2001
  ident: ref_9
  article-title: Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/S0960-894X(01)00344-4
  contributor:
    fullname: Barker
– volume: 378
  start-page: 113
  year: 2018
  ident: ref_20
  article-title: Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1713137
  contributor:
    fullname: Soria
– volume: 376
  start-page: 629
  year: 2016
  ident: ref_36
  article-title: Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1612674
  contributor:
    fullname: Mok
– volume: 113
  start-page: 101
  year: 2003
  ident: ref_27
  article-title: Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00232-0
  contributor:
    fullname: Ayad
– volume: 20
  start-page: 454
  year: 2020
  ident: ref_50
  article-title: CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01547-7
  contributor:
    fullname: Dou
– volume: 579
  start-page: 1488
  year: 2005
  ident: ref_26
  article-title: Cell-cycle-dependent regulation of the human and mouse Tome-1 promoters
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2005.01.055
  contributor:
    fullname: Yoshida
– volume: 350
  start-page: 2129
  year: 2004
  ident: ref_5
  article-title: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa040938
  contributor:
    fullname: Lynch
– volume: 12
  start-page: 6494
  year: 2006
  ident: ref_17
  article-title: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-1570
  contributor:
    fullname: Balak
– volume: 4
  start-page: e125693
  year: 2019
  ident: ref_49
  article-title: Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.125693
  contributor:
    fullname: Izadmehr
– ident: ref_42
  doi: 10.1016/j.cllc.2021.06.006
– volume: 11
  start-page: 515
  year: 2020
  ident: ref_51
  article-title: Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-2713-8
  contributor:
    fullname: Liu
– ident: ref_30
  doi: 10.1186/1471-2407-12-321
– volume: 4
  start-page: 1046
  year: 2014
  ident: ref_11
  article-title: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-14-0337
  contributor:
    fullname: Cross
– volume: 33
  start-page: 1965
  year: 2015
  ident: ref_29
  article-title: OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: A bioinformatic analysis combine with RNAi and oligonucleotide microarray
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2015.3792
  contributor:
    fullname: Hu
– volume: 11
  start-page: e121
  year: 2016
  ident: ref_21
  article-title: L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2016.05.019
  contributor:
    fullname: Bersanelli
– volume: 11
  start-page: 5228
  year: 2020
  ident: ref_38
  article-title: Non-invasive decision support for NSCLC treatment using PET/CT radiomics
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19116-x
  contributor:
    fullname: Mu
– volume: 69
  start-page: 3256
  year: 2009
  ident: ref_35
  article-title: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-4055
  contributor:
    fullname: Sos
– volume: 35
  start-page: 4027
  year: 2017
  ident: ref_14
  article-title: Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2017.73.9250
  contributor:
    fullname: Mok
– volume: 7
  start-page: 81598
  year: 2016
  ident: ref_37
  article-title: Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13150
  contributor:
    fullname: Tang
SSID ssj0000331767
Score 2.3410637
Snippet Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal...
Simple SummaryResistance to tyrosine kinase inhibitors (TKIs) that target common non-small-cell lung cancer mutations within the epidermal growth factor...
SourceID pubmedcentral
cristin
proquest
crossref
SourceType Open Access Repository
Aggregation Database
StartPage 4651
SubjectTerms Adenocarcinoma
Antibodies
Biomarkers
Cancer therapies
Casein
Casein kinase II
Cell culture
Cell cycle
Cell division
Chemotherapy
Enzyme inhibitors
Epidermal growth factor
Epidermal growth factor receptors
Kinases
Lung cancer
Mutants
Mutation
Non-small cell lung carcinoma
Patients
Phosphatase
Protein-tyrosine kinase receptors
Proteins
Small cell lung carcinoma
Tumors
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFLegkxAXxKcWNpCROHCxVn_EiU_TKCkbWyvUddJuUew4a6XgjqY9cOB_57007SgHbpEc6SV-X79nP70fIR9dhXWVUywuU8OULjSzRVmwysrS2kJw35L2jcb6_EZ9u41vuwO3pmur3MbENlCXC4dn5CcIjKGaMnH_9P4nQ9YovF3tKDQekwPBZZr2yMHnbPx9sjtl6UvIjzrZzPSRUN-fONzMZcPBlpEGHGCva70p7CemB7S53yv5V_IZPifPOtRIzzZqfkEe-fCSPBl19-KvyO-s9ni2Gu7o4MvgTNIr7AVqaBZm-CENnf4CofAqvZwHyFv0IszmFpx5Sa-xg31DIUHngU4vL9jEN4gqw4pmX4cTOlq3z-NFYNc_irpmA1_X9GqNwtrffE1uhtl0cM46YgXmlBArBhio8rZIOZTVCQAUZY0odaqscByjoxCeG-UrJPDkXLpSQjituAV4kvp-Gcs3pBcWwR8SalycOKOFqbRTvChtbCHnxYktdQXVXBGRw25_8wA2jfNIY5Eb2TciIp-2G57fb0ZrwHKOWsr_0VJEjrcKyTsfa_IHi4jIh90yeAdeeRTBL9btO4mKEddFJNlT5E4kztfeXwnzWTtnG0RDKpdv_y_8iDwV2OeCtBL6mPRWy7V_B0BlZd931vgHyNnqyg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pb9MwFLbYkNAuCBjTAgMZicMuZrVjO_UBoam0bGzdYWul3SLbcdZKmQtNK7ED_zvvpelG0cQtkhO95P3w-7746T1CPvoSeZWXTBVdw6S2mjlbWFa6tHDOCh6aoX3DC30ylt-v1fXDOKBWgfWj1A7nSY3n1adfP---QMB_RsYJlP3Io37mNQf3xMneW-SpgLSI9V3DFus323IKqVJnq_Y-jz0HCNg3gRU3c9QD8Nwsm_wrDw1ekOctgKTHK4u_JE9CfEWeDdsj8l3yu18F_M0ab2jva-84pedYFlTTfpzgi9R0dAdC4VZ6No2QwuhpnEwdxPWcXmEx-2qaBJ1GOjo7ZZehRoAZF7T_bXBJh8vm-mIW2dWtrSrWC1VFz5corPnM12Q86I96J6ydscC8FGLBAA6VwdkuB4adAVaRzohCd6UTnuNGKUTgRoYSZ3lynvoihZ215A6QSjd0CpXuke04i2GfUONV5o0WptRecls45SD9qcwVugRiZxOy3-o3j-De2JpUidykHSMScrhWeP5j1WUDlnO0Uv6PlRJysDZIvvaWHFkTUG2jOgn5cL8MgYKnHzaG2bK5J5MKIV5Csg1D3ovEVtubK3E6aVpug2jI6umb_wt_S3YElrzghAl9QLYX82V4B5hl4d43vvgHHkftOw
  priority: 102
  providerName: Scholars Portal
Title Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
URI https://www.proquest.com/docview/2576383950
https://search.proquest.com/docview/2577450256
http://hdl.handle.net/10852/93092
https://pubmed.ncbi.nlm.nih.gov/PMC8466783
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED7EKRpkKfpE1KYGC3TootjiQ48xVeUkTWQEjgN4E0SKigXIdGDZQ4f-9x5lOY07dhEEkAIp3h3v-8TTHcBXVVpepbgrijByuZ_7rsyL3C0lK6TMqafbon3p2L-85z9nYnYAYvcvTBu0r2R1ZurFmanmbWzl40INdnFig9s0Rp-Jeywb9KCH7vcZRW-3X4Yu0Q-2aXwYUvqBsuu3ajxUX1v5-xiOGBcBUgWElS9Va0tm3y39xZr7kZLPXM_oNbzqMCM5387tDRxo8xaO0u5U_B38Tmptv6yaBxL_iM8ZubGRQA1JzNzOqSHTXzgodiXXlUGvRa7MvJJoyityZ-PXtwUkSGXI9PrKnejGYkqzJsnFaELSTXs_Xhr3bpHXtRvruiY3GztY-8bv4X6UTONLtyur4CpO6dpFBFRqmYcekuoA4QmXES38kEuqPLs3Uqq9iOvSlu_0PKYKhptp6UkEJ6EeFoJ9gEOzNPoESKREoCKfRqWvuJcXUkj0eCKQhV8il8sdOOnWNzOo0TYbqaBZxIYRdeDbbsGzx21iDWzOrMCyfwTmwOlOIFlnYU1miRKy60gMHfjy1Iy2YQ88cqOXm7ZPwIVFdQ4Ee4J8GtJm195vQaVrs2x3Svbxv5_8BMfUBsDYehP-KRyuVxv9GRHMWvbhxfdkfDvpQ-9i5uE15WG_1eI_wPn11A
link.rule.ids 230,314,727,780,784,885,2221,21388,24318,27924,27925,33744,33745,43805,53791,53793,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB5BKkEviKdqaGGROHBZNV571_EJtcEhIQ-hNJV6s7zrdRPJ3ZQ4OXDgvzPjOCnhwM3SWhp75_XN7mg-gE-moLrKhFzmnZiHKlNcZ3nGCx3kWmfCtzVp33ii-tfh9xt50xy4VU1b5S4m1oE6Xxo6Iz8nYIzVVCzbX-5_cmKNotvVhkLjMRzR5HTZgqPLZPJjuj9laQeYH1W0nekTYH1_bmgzV5WPtkw04Ah7Te1N7jAxPaDNw17Jv5JP7zk8a1Aju9iq-QU8su4lPBk39-Kv4HdSWjpbdbes-7V7EbAR9QJVLHFz-pCKzX6hUHyVDRcO8xYbuPlCozOv2BV1sG8pJNjCsdlwwKe2IlTp1iz51puy8aZ-niwdv7rLypJ3bVmy0YaE1b_5Gq57yazb5w2xAjehEGuOGKiwOuv4WFZHCFBCHYtcdUItjE_RUQjrx6EtiMDT9wOTBxhOC18jPOnYdi6DN9ByS2dPgMVGRiZWIi6UCf0s11JjzpORzlWB1VzmwUmzv6lDm6Z5pFKkcdCOhQefdxue3m9Ha-BySlpK_9GSB6c7haSNj1Xpg0V48HG_jN5BVx6Zs8tN_U4USsJ1HkQHityLpPnahytuMa_nbKNoTOXB2_8L_wBP-7PxKB0NJsN3cCyo54UoJtQptNarjT1D0LLW7xvL_APkzu2y
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEB5aB0IvJemDqEnTLfTQy2Jp9bJOIXXkxvWD4DiQm9CuVrFBXaeWfcih_70z8tqpe-hNsIKRdl7f7A7zAXxRJdVVKuBh0Ul4EOURl3mR81L6hZS58HRD2jcaR9d3wY_78N72P9W2rXIbE5tAXSwUnZG3CRhjNZWEbru0bRE3V72Lx1-cGKToptXSabyEA8yKrmjBwbd0fDPZnbi4PubKKN7M9_Gx1m8r2thl7aFdEyU4QmDVeJbZT1LPyHO_b_KvRNQ7gtcWQbLLjcqP4YU2b-BwZO_I38LvtNJ0zmoeWPeqe-mzIfUF1Sw1M_qQmk2fUCi-ygZzgzmM9c1sLtGxl-yWutk3dBJsbth00OcTXRPCNCuWfu9N2GjdPI8Xht_-zKuKd3VVseGahDW_-Q7ueum0e80tyQJXgRArjnio1DLveFhixwhWApmIIuoEUiiPIqUQ2ksCXRKZp-f5qvAxtJaeRKjS0W4R-u-hZRZGnwBLVBirJBJJGanAywsZSsx_YSyLqMTKLnfgxO5vZtC-aTZpKLLEdxPhwNfthmePmzEbuJyRlrJ_tOTA2VYhmfW3Onu2Dgc-75bRU-j6Izd6sW7eiYOQMJ4D8Z4idyJp1vb-ipnPmpnbKBrTuv_h_8I_wSEaZTbsjwen8EpQ-wuxTURn0Fot1_oj4peVPLeG-QfLg_Hf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevating+CDCA3+Levels+Enhances+Tyrosine+Kinase+Inhibitor+Sensitivity+in+TKI-Resistant+EGFR+Mutant+Non-Small-Cell+Lung+Cancer&rft.jtitle=Cancers&rft.au=Sahin%2C+Katherine+B&rft.au=Shah%2C+Esha+T&rft.au=Ferguson%2C+Genevieve+P&rft.au=Molloy%2C+Christopher&rft.date=2021-09-16&rft.pub=MDPI+AG&rft.eissn=2072-6694&rft.volume=13&rft.issue=18&rft.spage=4651&rft_id=info:doi/10.3390%2Fcancers13184651&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon